2/4
03:25 pm
axsm
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer's Label Hopes [Yahoo! Finance]
Low
Report
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer's Label Hopes [Yahoo! Finance]
2/3
08:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a "buy" rating on the stock.
2/3
07:13 am
axsm
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates [Yahoo! Finance]
Low
Report
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates [Yahoo! Finance]
1/29
10:04 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
1/28
02:29 pm
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.
1/27
07:07 am
axsm
Top Picks 2026- Dynex Capital Inc. DX [Yahoo! Finance]
Low
Report
Top Picks 2026- Dynex Capital Inc. DX [Yahoo! Finance]
1/27
07:00 am
axsm
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
Low
Report
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
1/24
06:45 am
axsm
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline [Seeking Alpha]
Low
Report
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline [Seeking Alpha]
1/23
04:36 pm
axsm
How The New Price Target Is Shaping The Axsome Therapeutics (AXSM) Investment Story [Yahoo! Finance]
Low
Report
How The New Price Target Is Shaping The Axsome Therapeutics (AXSM) Investment Story [Yahoo! Finance]
1/23
07:41 am
axsm
Assessing Axsome Therapeutics (AXSM) Valuation After Analyst Upgrades And Pipeline Progress [Yahoo! Finance]
Low
Report
Assessing Axsome Therapeutics (AXSM) Valuation After Analyst Upgrades And Pipeline Progress [Yahoo! Finance]
1/23
05:06 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
07:17 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/20
08:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at HC Wainwright from $200.00 to $260.00. They now have a "buy" rating on the stock.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at HC Wainwright from $200.00 to $260.00. They now have a "buy" rating on the stock.
1/16
08:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/15
07:00 am
axsm
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
Low
Report
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
1/14
08:42 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/13
10:58 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was given a new $209.00 price target on by analysts at Robert W. Baird.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was given a new $209.00 price target on by analysts at Robert W. Baird.
1/13
08:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/12
04:54 pm
axsm
MoneyShow's Best Investment Ideas For 2026: Part 2 [Seeking Alpha]
Low
Report
MoneyShow's Best Investment Ideas For 2026: Part 2 [Seeking Alpha]
1/12
07:00 am
axsm
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Low
Report
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
1/8
08:02 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.
1/8
08:02 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.
1/6
09:02 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/5
08:42 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
1/5
07:03 am
axsm
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.